EUVIMEDEUVIMED entdecken
Open Access

Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers

Isaac Allen iD, Hend Hassan iD, Yvonne Walburga iD, Catherine Huntley iD, Lucy Loong iD, Tameera Rahman, Sophie Allen iD, Alice Garrett iD, Bethany Torr iD, Andrew Bacon, Craig Knott, Sophie Jose iD und 15 weitere

Journal of Clinical Oncology · 20.02.2025 · 43 (6) · 651-661

DOI: 10.1200/jco.24.01146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2025. Verfasst von Isaac Allen und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Breast Neoplasms, BRCA2 Protein, BRCA1 Protein. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Second primary cancer (SPC) risks after breast cancer (BC) in BRCA1/BRCA2 pathogenic variant (PV) carriers are uncertain. We estimated relative and absolute risks using a novel linkage of genetic testing data to population-scale National Disease Registration Service and Hospital Episode Statistics electronic health records. METHODS We followed 25,811 females and 480 males diagnosed with BC and tested for germline BRCA1/BRCA2 PVs in NHS Clinical Genetics centers in England between 1995 and 2019 until SPC diagnosis, death, migration, contralateral breast/ovarian surgery plus 1 year, or the 31st of December 2020. We estimated standardized incidence ratios (SIRs) using English population incidences, hazard ratios (HRs) comparing carriers to noncarriers using Cox regression, and Kaplan-Meier 10-year cumulative risks. RESULTS There were 1,840 BRCA1 and 1,750 BRCA2 female PV carriers. Compared with population incidences, BRCA1 carriers had elevated contralateral BC (CBC; SIR, 15.6 [95% CI, 11.8 to 20.2]), ovarian (SIR, 44.0 [95% CI, 31.4 to 59.9]), combined nonbreast/ovarian (SIR, 2.18 [95% CI, 1.59 to 2.92]), colorectal (SIR, 4.80 [95% CI, 2.62 to 8.05]), and endometrial (SIR, 2.92 [95% CI, 1.07 to 6.35]) SPC risks. BRCA2 carriers had elevated CBC (SIR, 7.70 [95% CI, 5.45 to 10.6]), ovarian (SIR, 16.8 [95% CI, 10.3 to 26.0]), pancreatic (SIR, 5.42 [95% CI, 2.09 to 12.5]), and combined nonbreast/ovarian (SIR, 1.68 [95% CI, 1.24 to 2.23]) SPC risks. Compared with females without BRCA1/BRCA2 PVs on testing, BRCA1 carriers had elevated CBC (HR, 3.60 [95% CI, 2.65 to 4.90]), ovarian (HR, 33.0 [95% CI, 19.1 to 57.1]), combined nonbreast/ovarian (HR, 1.45 [95% CI, 1.05 to 2.01]), and colorectal (HR, 2.93 [95% CI, 1.53 to 5.62]) SPC risks. BRCA2 carriers had elevated CBC (HR, 2.40 [95% CI, 1.70 to 3.40]), ovarian (HR, 12.0 [95% CI, 6.70 to 21.5]), and pancreatic (HR, 3.56 [95% CI, 1.34 to 9.48]) SPC risks. Ten-year cumulative CBC, ovarian, and combined nonbreast/ovarian cancer risks were 16%/6.3%/7.8% ( BRCA1 carriers), 12%/3.0%/6.2% ( BRCA2 carriers), and 3.6%/0.4%/4.9% (noncarriers). Male BRCA2 carriers had higher CBC (HR, 13.1 [95% CI, 1.19 to 146]) and prostate (HR, 5.61 [95% CI, 1.96 to 16.0]) SPC risks than noncarriers. CONCLUSION Survivors of BC carrying BRCA1 and BRCA2 PVs are at high SPC risk. They may benefit from enhanced surveillance and risk-reduction measures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Second PrimaryBreast NeoplasmsBRCA2 ProteinBRCA1 ProteinHumansFemaleMiddle AgedAdultMaleHeterozygoteIncidenceAgedGenetic Predisposition to DiseaseGerm-Line MutationEnglandRisk FactorsRisk Assessment

Substanzen

BRCA2 ProteinBRCA2 protein, humanBRCA1 protein, humanBRCA1 Protein

Autor:innen und Institutionen

  • Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • National Disease Registration Service, National Health Service England, London, United Kingdom.
  • Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, United Kingdom.
  • Health Data Insight CIC, Cambridge, United Kingdom.
  • Department of Clinical Genetics, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
  • Centre for Cancer, Society and Public Health, Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.

ORCID-Profile: Isaac Allen, Hend Hassan, Yvonne Walburga, Catherine Huntley, Lucy Loong, Sophie Allen, Alice Garrett, Bethany Torr, Sophie Jose, Sally Vernon, Joanna Pethick, Francesco Santaniello, Ying-Wen Wang, Fiona McRonald, Diana Eccles, Clare Turnbull, Marc Tischkowitz, Paul Pharoah, Antonis C Antoniou

Förderung

  • Wellcome Trust

Zitieren

APA

Allen, I., Hassan, H., Walburga, Y., Huntley, C., Loong, L., Rahman, T., Allen, S., Garrett, A., Torr, B., Bacon, A., Knott, C., Jose, S., Vernon, S., Lüchtenborg, M., Pethick, J., Santaniello, F., Goel, S., Wang, Y. W., Lavelle, K., …, & Antoniou, A. C. (2025). Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers. Journal of Clinical Oncology, 43(6), 651-661. https://doi.org/10.1200/jco.24.01146

Vancouver

Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, et al. Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers. Journal of Clinical Oncology. 2025;43(6):651-661. doi:10.1200/jco.24.01146

BibTeX
@article{Allen2025,
  author = {Allen, Isaac and Hassan, Hend and Walburga, Yvonne and Huntley, Catherine and Loong, Lucy and Rahman, Tameera and Allen, Sophie and Garrett, Alice and Torr, Bethany and Bacon, Andrew and Knott, Craig and Jose, Sophie and Vernon, Sally and Lüchtenborg, Margreet and Pethick, Joanna and Santaniello, Francesco and Goel, Shilpi and Wang, Ying-Wen and Lavelle, Katrina and McRonald, Fiona and Eccles, Diana and Morris, Eva and Hardy, Steven and Turnbull, Clare and Tischkowitz, Marc and Pharoah, Paul and Antoniou, Antonis C},
  title = {Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {6},
  pages = {651--661},
  doi = {10.1200/jco.24.01146}
}
Kostenlos starten →